miR-205: A Potential Biomedicine for Cancer Therapy
- PMID: 32854238
- PMCID: PMC7564275
- DOI: 10.3390/cells9091957
miR-205: A Potential Biomedicine for Cancer Therapy
Abstract
microRNAs (miRNAs) are a class of small non-coding RNAs that regulate the expression of their target mRNAs post transcriptionally. miRNAs are known to regulate not just a gene but the whole gene network (signaling pathways). Accumulating evidence(s) suggests that miRNAs can work either as oncogenes or tumor suppressors, but some miRNAs have a dual nature since they can act as both. miRNA 205 (miR-205) is one such highly conserved miRNA that can act as both, oncomiRNA and tumor suppressor. However, most reports confirm its emerging role as a tumor suppressor in many cancers. This review focuses on the downregulated expression of miR-205 and discusses its dysregulation in breast, prostate, skin, liver, gliomas, pancreatic, colorectal and renal cancers. This review also confers its role in tumor initiation, progression, cell proliferation, epithelial to mesenchymal transition, and tumor metastasis. Restoration of miR-205 makes cells more sensitive to drug treatments and mitigates drug resistance. Additionally, the importance of miR-205 in chemosensitization and its utilization as potential biomedicine and nanotherapy is described. Together, this review research article sheds a light on its application as a diagnostic and therapeutic marker, and as a biomedicine in cancer.
Keywords: Targeted Delivery; cancer; miR-205; miRNAs; nanoformulation; tumor suppressor.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
MicroRNA-221: biogenesis, function and signatures in human cancers.Eur Rev Med Pharmacol Sci. 2018 May;22(10):3094-3117. doi: 10.26355/eurrev_201805_15069. Eur Rev Med Pharmacol Sci. 2018. PMID: 29863255 Review.
-
miRNA and cancer; computational and experimental approaches.Curr Pharm Biotechnol. 2014;15(5):429. doi: 10.2174/138920101505140828161335. Curr Pharm Biotechnol. 2014. PMID: 25189575
-
miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance.J Mol Med (Berl). 2016 Jun;94(6):629-44. doi: 10.1007/s00109-016-1420-5. Epub 2016 Apr 20. J Mol Med (Berl). 2016. PMID: 27094812 Review.
-
Therapeutic targeting of miRNA-216b in cancer.Cancer Lett. 2020 Aug 1;484:16-28. doi: 10.1016/j.canlet.2020.04.020. Epub 2020 May 5. Cancer Lett. 2020. PMID: 32387443 Review.
-
MicroRNAs: master regulators of drug resistance, stemness, and metastasis.J Mol Med (Berl). 2014 Apr;92(4):321-36. doi: 10.1007/s00109-014-1129-2. Epub 2014 Feb 9. J Mol Med (Berl). 2014. PMID: 24509937 Review.
Cited by
-
MicroRNA based combinatorial therapy against TKIs resistant CML by inactivating the PI3K/Akt/mTOR pathway: a review.Med Oncol. 2023 Sep 15;40(10):300. doi: 10.1007/s12032-023-02161-z. Med Oncol. 2023. PMID: 37713129 Review.
-
LncRNA CYP4A22-AS1 promotes the progression of lung adenocarcinoma through the miR-205-5p/EREG and miR-34c-5p/BCL-2 axes.Cancer Cell Int. 2023 Sep 5;23(1):194. doi: 10.1186/s12935-023-03036-z. Cancer Cell Int. 2023. PMID: 37670265 Free PMC article.
-
Simple and sensitive detection of miRNA-122 based on a micro-biosensor through square wave voltammetry.RSC Adv. 2023 Jul 17;13(31):21414-21420. doi: 10.1039/d3ra03759b. eCollection 2023 Jul 12. RSC Adv. 2023. PMID: 37465577 Free PMC article.
-
Epigenetic and Immunological Features of Bladder Cancer.Int J Mol Sci. 2023 Jun 7;24(12):9854. doi: 10.3390/ijms24129854. Int J Mol Sci. 2023. PMID: 37373000 Free PMC article. Review.
-
Deregulated microRNAs Involved in Prostate Cancer Aggressiveness and Treatment Resistance Mechanisms.Cancers (Basel). 2023 Jun 10;15(12):3140. doi: 10.3390/cancers15123140. Cancers (Basel). 2023. PMID: 37370750 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
